Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this run over
GNPX did two offerings apparently. Feb and maybe Dec.
Hopefully a lot of these latest pops in the last month or so has share offerings to dilute the share. Just if anything big to the downside maybe average down. This is a tough stock to trade. But now the outstanding shares are low. So maybe a day or two more of runs then maybe a dilusion as others have also pointed out.
Is there room to run here? Based on the move today and the news yesterday with Coronavirus. Will they be able to help globally fight this? What’s the bigger impacted?
I did something similar as well.
1. uniQure Nv (QURE) 2.6 Billion
2. Regenxbio (RGNX) 1.96 Billion
3. Audentes Theapeatics Inc (BOLD) bought out
4. Solid Biosciences (SLDB) 150 Million note: Failed Clinical though
5. Meira GTx Holdings (MGTX) 670 Million
6. Voyager Therapeutics (VYGR) 500 Million
7. Sarepta Therapeutics (SRPT) 9.5 Billion
Note here I dnt know what these other companies also have in terms of assets etc. But based on a failed clinical the base for this stock is 150 Million. Realistically its prob worth around 375 - 600 Million. If I am not mistaken they will be conducting clinicals soon? If that continues with success then 1 Billion at minimum?
"The successful closing of this transaction is further evidence that our corporate vision and proprietary technology in the gene therapy cancer treatment market are gaining traction with institutional investors," commented Rodney Varner, Chief Executive Officer at Genprex. "This offering will provide additional resources for further development of our technologies, including the planned clinical trial of our Oncoprex™ immunogene therapy in combination with osimertinib (marketed as Tagrisso® by Astra Zeneca) for which we recently received a U.S. FDA Fast Track Designation, and our planned clinical trial of Oncoprex immunogene therapy combined with pemrolizumab (marketed as Keytruda by Merck & Co), both in non-small cell lung cancer, as well as further development of our pre-clinical gene therapy for Type 1 and Type 2 diabetes which we recently in-licensed from the University of Pittsburgh. We are excited to advance these new drug candidates toward potential availability for treatment of these serious diseases in large patient populations with unmet medical needs."
https://www.reuters.com/article/us-audentes-m-a-astellas-pharma/japans-astellas-to-buy-audentes-for-3-billion-in-high-priced-gene-therapy-bet-idUSKBN1Y62IN
Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy bet.
“Roche Holding AG, the Swiss drug giant that said it would pay $4.3 billion in cash to buy Philadelphia-based gene therapy developer Spark Therapeutics in February, has posted another delay.”
“Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together, Roche and Spark will be able to significantly improve the lives of patients through innovative gene therapies. This acquisition supports our long-lasting commitment to bringing transformational therapies and innovative approaches to people around the world with serious diseases.” “
“Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. “
Is the other gene therapy company that was bought out in the same stage as GNPX? Or does GNPX still have to prove something before a billion valuation.
Are we building a base here?
Are we building a base here?
Are we building a base here?
Unless it’s not over yet. 85 million shares changed hands. Likely more folks are in this as well.
Yeah and that numbers as of Sept 30th, 2020. They are the largest institutional investor. Next up is RENAISSANCE TECHNOLOGIES LLC 200k as of Dec 31st, 2020
They own 10%? It appears that 50% is locked by insiders.
Its trading side ways. A lot of traders are fearing it will drop because of the large run. But the stock has a lot of value and showing strength. Once the folks selling and buying quickly start to hold they will see this back to $5
Is delisting no longer an issue?
Whats the float on this one? Good entry here? Or as the CEO said, doesnt deserve evaluation?
is rlog going to be delisted or have they meet nasdaq requirements?
http://www.nasdaq.com/press-release/aethlon-medical-announces-compliance-with-nasdaq-listing-criteria-20171010-01076
I think this should resolve any fears.
Who are the holders?
the RS?
what is the current outstanding shares and float?
Did they do an equity offering?
Stock looks very interesting.
Pushing higher? Retest maybe...
Whats going on?
who is wainwright? I didnt follow what you ment? 3.5 or 4 dollars?
Winwright?
Okat results were already out march 10
I cant find news. Did they release results?
After hours looking good.
Why did auph run?
Maybe one last test to 1.4 but much higher prices coming.
Good then we pop tomorrow.
But it is tomorrow
I also read that they were suppose to release on March 2nd. Not sure if that article is incorrect.
Ocera Therapeutics, Inc. is estimated to report earnings on 03/09/2017.
Read more: http://www.nasdaq.com/earnings/report/ocrx#ixzz4aldw5O24
Also the float has traded 2 times. This is definitely going much higher in a few days.
The data sounds very good. And a market they can tap into. I just saw that they expect some new trials in the next quarter? So I wonder how far out are they? Based on the potential is this easily worth over atleast 50Million? When do they expect the first revenues in best case timeframe?